Related Experiment Video
Updated: Feb 7, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Cysteine-targeted Irreversible Inhibitors of Tyrosine Kinases and Key Interactions
1College of Chemistry & Chemical Engineering, Shaoxing University, Shaoxing 312000, P.R., China.
Abstract:
Tyrosine kinases are a subgroup of a large class of protein kinases that transfer phosphate groups from ATP to various amino acid residues. By phosphorylating the tyrosine residues, the tyrosine kinases are responsible for the activation of various proteins through signal transduction cascades, which serves as a ubiquitous mechanism of cell signaling. The frequent success of many tyrosine kinase inhibitors (TKIs) in clinical success and diseasecausing mutations in protein kinases suggests that a large number of kinases may represent therapeutically relevant targets. To date, most of the clinical and preclinical TKIs are ATPcompetitive non-covalent inhibitors, which achieve their selectivity by recognizing the unique features of specific protein kinases. Of growing interest now in the scientific community is the development of irreversible inhibitors that form covalent bonds with cysteines or other nucleophilic residues in the ATP binding pocket. Irreversible TKIs have many potential advantages including prolonged pharmacodynamics, reasonable compound design suitability, high potency, and the ability to validate pharmacological specificity by mutations in reactive cysteine residues. Here, we review recent efforts to develop cysteine-targeting irreversible TKIs and to discuss their patterns of configuration that identify adenosine triphosphate binding pockets and their biological activities.
Insights
Irreversible tyrosine kinase inhibitors (TKIs) targeting cysteine residues offer advantages over traditional drugs. These covalent inhibitors show promise for developing more effective and specific cancer therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Tyrosine kinases are crucial enzymes in cell signaling, regulating protein activation via phosphorylation.
- Mutations in tyrosine kinases are implicated in various diseases, making them significant therapeutic targets.
- Current tyrosine kinase inhibitors (TKIs) are mostly non-covalent and ATP-competitive.
Purpose of the Study:
- To review recent advancements in the development of irreversible TKIs.
- To discuss the design strategies for cysteine-targeting irreversible TKIs.
- To explore the therapeutic potential and biological activities of these novel inhibitors.
Main Methods:
- Review of recent scientific literature on irreversible TKIs.
- Analysis of inhibitor configurations targeting ATP binding pockets.
- Discussion of structure-activity relationships and pharmacological validation.
Main Results:
- Irreversible TKIs form covalent bonds with nucleophilic residues like cysteine in the ATP binding pocket.
- These inhibitors offer potential advantages such as prolonged pharmacodynamics and high potency.
- Specific design patterns enable recognition of unique features within kinase ATP binding sites.
Conclusions:
- Cysteine-targeting irreversible TKIs represent a promising new class of therapeutics.
- Their development offers enhanced specificity and potency compared to conventional TKIs.
- Further research into irreversible TKIs could lead to more effective treatments for kinase-driven diseases.
More Related Videos
Related Concept Videos
01:26Receptor Tyrosine Kinases
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:54Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
02:54Protein Kinases and Phosphatases
01:14Reversible and Irreversible Processes
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...